Preoperative Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes: A Prospective Multi-Institutional Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Glioma
- Sponsor
- Sun Yat-sen University
- Enrollment
- 1282
- Locations
- 3
- Primary Endpoint
- all-cause mortality
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.
Investigators
Yonggao Mou
Clinical Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria;
- •age \> 18 years;
- •primary malignant glioma;
- •the duration of follow-up \> 3 months;
- •available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization.
- •Exculsion Criteria:
- •current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition;
- •prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
all-cause mortality
Time Frame: 16 years
For this study, the endpoint was all-cause mortality. Time zero was set at the time of resection of the primary tumor.